12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lantus insulin glargine: Additional Phase III data

Additional data from the open-label, international Phase III ORIGIN trial in 12,537 pre-diabetics or early Type II diabetics with cardiovascular risk factors showed that patients on Lantus were about 3 times more likely to achieve and maintain HbA1c <6.5% over 5 years compared to standard of care (SOC) consisting of investigator's best judgment over the 6-year study (p<0.001). Lantus was more effective at maintaining glycemic control than...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >